Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Potassium voltage-gated channel subfamily A regulatory beta subunit 1 (KCNAB1) encodes a cytoplasmic regulatory (beta-1) subunit of the shaker-like voltage-gated potassium channels. The KCNAB1 protein forms complexes with Kv1 alpha subunits and modulates the gating kinetics and inactivation, particularly contributing to fast N-type inactivation. This finely tunes potassium currents that control neuronal repolarization and repetitive firing, as well as transient and slow K+ currents in cardiac myocytes. KCNAB1 also possesses NADPH-dependent aldo-keto reductase activity, which can influence channel function. Mutations and changes in KCNAB1 activity are implicated in disorders such as epilepsy, episodic ataxia, and contribute to cardiovascular rhythm control and vascular smooth muscle biology[1][2][3].
Modulation of N-type (fast) inactivation of Kv channels, affecting neuronal and cardiac excitability. Drugs that modulate Kv channel availability, repolarization, or inactivation may act via complexes containing KCNAB1.
4 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Potassium voltage-gated channel subfamily A regulatory beta subunit 1 (KCNAB1).